Blincyto (Blinatumomab), a bispecific T-cell engager, was granted accelerated approval for treating Relapsed/Refractory Acute Lymphoblastic Leukemia. Similarly to Kymriah, this decision was based on a ...

In the Philippines, few developments reflect this shift more clearly than the Mall of Asia (MOA) complex in Pasay City. Across a single district, MOA brings together a rare convergence ...

Key growth drivers (not an exhaustive list) include Tezspire, an asthma medication; Repatha, which treats high cholesterol; and blood-cancer medicine Blincyto. Like every drugmaker, Amgen will ...

While the UHC Law was enacted in 2019, progress on this specific provision had stalled. “This MOA is more than just a formal document. It’s a symbol of shared vision, trust, and commitment.

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones ...

Coming back to the first-quarter results, sales of most of its products, like Prolia, Xgeva, Repatha, Blincyto and Evenity, beat estimates. Fourteen products, including Repatha, Blincyto ...

Coming back to the first-quarter results, sales of most of its products, like Prolia, Xgeva, Repatha, Blincyto and Evenity, beat estimates. Fourteen products, including Repatha, Blincyto, Tezspire, ...

NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.

Key products gaining traction include Blincyto, a revolutionary blood cancer treatment for B-cell acute lymphoblastic leukemia, and Evenity, a best-in-class osteoporosis treatment. Several early ...